Personalized
GLP-1 Dosing for Better Clinical Outcomes
Personalized dosing suggestions
Visualize patient weight loss journeys
Improve shared decision-making
Shareable patient report with treatment progress

15K+
patients
Built from insights across
real-world patient data
25+
studies
Informed by clinical trials
and PK/PD models
>50% of Patients Discontinue GLP-1 Treatment Within 12 Months[1]
WeDosify helps clinicians deliver the right dose, at the right time, improving adherence and protecting revenue.
Personalize Treatment
Increase Adherence
Improve Patient Satisfaction
Differentiate Your Service
Key Features
Generate personalized dose regimens, whether you are starting a treatment or adjusting mid-journey.
Dosing Initiation & Review
Semaglutide and tirzepatide dosing plans tailored to align with your organization’s treatment protocols.
Customizable GLP-1 Dosing
Clear Treatment Planning
Keep patient weight loss journeys on track with detailed treatment information and predictions.
Shareable Patient Reports
Support and motivate patients with clear and structured treatment progress reports.
Testimonials
“Having data helps you make personalized decisions and makes you more engaged with your weight loss journey.”
Anonymous patient
“For a big enterprise with thousands of patients and many providers, I think it’s a very valuable tool.”
Dr. Odhett Cojocaru
Internist & Obesity Specialist
“It makes me feel engaged and positive, taking an active part in my health journey.”
Anonymous patient
Why WeDosify
IP Protected
Work-flow Friendly
Enhanced Future Value
Evidence-based Insights
Partner Customizable
Intelligent Dosing
Truly Personalized Care
Easy Integration
Closed Loop Medicine
WeDosify is manufactured by Closed Loop Medicine (CLM). Closed Loop Medicine specializes in data-driven personalized dosing solutions, combining real-world pharmacology with data science to deliver predictive insights that help patients stay on treatment and achieve better health outcomes.
Privacy Statement
The use of the tool is fully compliant with clinical privacy standards, and no identifiable patient information is required at any point. More details available in the Privacy Policy.
References
1. Buse JB, Bajaj HS, Blonde L, et al. Real-world treatment patterns and discontinuation among GLP-1 receptor agonist users with type 2 diabetes. Diabetes Obes Metab. 2024. PubMed